Crape Jasmine: Cognitive and Neuroprotective Claims, Acetylcholinesterase Inhibition

This is the deepest, most reproducible, most independently-confirmed evidence base anywhere in crape jasmine’s literature — and it is also, tellingly, the claim the plant is least marketed for. Since 2003, at least four separate Thai research groups, working in overlapping but distinct laboratories, have repeatedly found that crape jasmine extracts and specific isolated alkaloids inhibit acetylcholinesterase, the same enzyme that donepezil, rivastigmine and galantamine — the actual approved Alzheimer’s drugs — are built to inhibit. This page takes that literature seriously, on its own terms, including the one design flaw that recurs through it and the one already-known ceiling that caps how excited any of it should make a reader.

Table of Contents

  1. What Is Actually Being Claimed
  2. The Screening Study That Started It
  3. Naming the Specific Alkaloids
  4. From Enzyme Assay to Living Tissue
  5. Quantifying Potency, and Building a Delivery System
  6. The Amyloid-Beta Mouse Study, and Why the Design Matters
  7. A Traditional “Brain Tonic” Claim, Tested a Different Way
  8. The Mechanism Ceiling: What Approved Drugs Already Show
  9. The Same Mechanism, Both Ways
  10. What Would Actually Settle This
  11. Evidence Ledger for This Page
  12. Practical Guidance
  13. Key Research Papers
  14. Connections

What Is Actually Being Claimed

The claim is specific and mechanistic, which is unusual for this plant and worth taking seriously for exactly that reason: crape jasmine extract, and several individual alkaloids purified from it, inhibit acetylcholinesterase — the enzyme that breaks down acetylcholine, the neurotransmitter most directly implicated in memory and attention, at synapses in the brain. Inhibiting that enzyme raises acetylcholine levels, which is the identical mechanism behind every acetylcholinesterase-inhibitor drug approved for Alzheimer’s disease. A second, related claim — that the plant protects neurons from the kind of damage seen in Alzheimer’s pathology — rests on a single mouse study discussed in detail below, and needs a sharper caveat than the enzyme-inhibition claim does.

The Screening Study That Started It

This entire research line traces to a single 2003 paper in the Journal of Ethnopharmacology, in which a Thai pharmacognosy group systematically screened plants used in traditional Thai rejuvenating and neurotonic remedies for acetylcholinesterase-inhibiting activity — a rational, hypothesis-driven approach, since traditional formulas aimed at mental vigour and memory are a sensible place to look for compounds that affect this specific enzyme system. Crape jasmine extract screened positive. That single finding launched two decades of follow-up work from overlapping Thai research groups, most of them centred on Naresuan University and Chiang Mai University. A 2021 genus-wide review of Tabernaemontana alkaloid chemistry independently confirms cholinergic and central-nervous-system activity as a recurring, reproducible theme across the genus rather than a one-laboratory artefact, which is consistent with how many separate Thai groups kept finding the same underlying property.

Back to Table of Contents

Naming the Specific Alkaloids

Follow-up work did not stop at “the extract is active” — it identified which molecules were responsible, which is exactly the kind of specificity the evidence doctrine on this site rewards over a vague whole-plant claim.

A 2006 paper in the Journal of Pharmacy and Pharmacology used bioassay-guided fractionation — testing progressively purified fractions of crape jasmine root extract against the enzyme using the standard Ellman colorimetric method, isolating whichever fraction retained activity, and repeating — to isolate two specific bisindole alkaloids: 19,20-dihydrotabernamine and 19,20-dihydroervahanine A. Both inhibited acetylcholinesterase more potently in vitro than galanthamine, an actual approved acetylcholinesterase-inhibitor drug used as the comparison standard. The inhibition by 19,20-dihydroervahanine A was further shown to be specific, reversible and competitive — meaning it competes directly with acetylcholine at the enzyme’s active site rather than binding elsewhere and gumming up the works irreversibly, which is pharmacologically the safer of the two general modes of enzyme inhibition. The same purification process also isolated two structurally related but inactive bisindole alkaloids, conodurine and tabernaelegantine A — a useful negative result, since it lets researchers start mapping which specific parts of the molecule’s structure the activity actually depends on.

A second alkaloid, 3′-R/S-hydroxyvoacamine, was isolated from crape jasmine stem extract in a 2013 Phytomedicine paper, guided again by the enzyme assay. This one was characterised quantitatively: a non-competitive inhibitor (working by a different mechanism than the two 2006 alkaloids) with a measured IC50 — the concentration needed to inhibit half of the enzyme’s activity — of 7.00 ± 1.99 micromolar, present at 12.4% by weight of the alkaloid-enriched stem fraction. A quantified IC50 for a named, structurally characterised compound is about as far as this kind of preclinical chemistry can honestly be pushed before it needs a living system to mean anything — which is exactly where the next studies went.

Back to Table of Contents

From Enzyme Assay to Living Tissue

Two studies moved this claim out of a test tube and into a functioning nervous system, and both are worth describing precisely.

A 2007 study in the Journal of Ethnopharmacology gave crape jasmine extract to live rats at three doses (250, 500 and 1000 mg/kg) and measured both cortical and circulating acetylcholinesterase activity directly, alongside Fos protein expression — a standard marker of recent neuronal activity — in the cerebral cortex. All three doses significantly inhibited cortical enzyme activity and increased Fos expression within two hours of a single dose, with no meaningful difference in effect size between the three doses tested. Circulating (blood) enzyme activity was also inhibited, but only transiently, in the first hour after dosing. This is a real in-vivo pharmacodynamic result: a single oral dose measurably changed both enzyme activity and a marker of neuronal activity in a living rat’s brain within two hours.

A companion 2010 study from an overlapping author group went further, using isolated rat hippocampal brain slices — the hippocampus being the brain region most directly involved in forming new memories — and measuring field excitatory postsynaptic potentials, a direct electrophysiological readout of synaptic signal strength. Crape jasmine extract significantly reduced these potentials, an effect blocked by atropine (which blocks a specific class of acetylcholine receptor, the muscarinic type) but not by pancuronium (which blocks the other main class, nicotinic), pointing to a muscarinic-receptor-dependent mechanism. The size and character of the effect resembled galanthamine’s known action in the same tissue preparation. This is genuine electrophysiology, not a behavioural proxy, and it is a meaningfully different and more direct kind of evidence than a rodent maze or recognition test would provide — though it is also, by its nature, entirely about isolated tissue rather than a behaving animal.

Back to Table of Contents

Quantifying Potency, and Building a Delivery System

One further line of work, separate from pure pharmacology, is worth including because it shows real applied research investment beyond simple screening: a 2013 paper in the International Journal of Pharmaceutics took the acetylcholinesterase-inhibiting alkaloidal extract from crape jasmine and formulated it into microemulsion and liquid-crystalline delivery systems — combined with Zingiber cassumunar (plai) oil, a surfactant, ethanol and water — explicitly aimed at improving transdermal delivery, tested using excised stillborn-piglet skin as a standard permeation model. Certain formulations both preserved acetylcholinesterase-inhibiting activity and measurably increased how much of the extract crossed the skin barrier within twenty-four hours. The authors framed this as a step toward an alternative percutaneous (through-the-skin) delivery route for raising acetylcholine levels in Alzheimer’s patients — genuine pharmaceutical-engineering interest in this plant’s chemistry, still entirely preclinical, using a non-human skin model, with no human pharmacokinetic or efficacy data attached.

The Amyloid-Beta Mouse Study, and Why the Design Matters

The most clinically-styled study in this literature, and the one that most needs its design read carefully before its result is repeated, is a 2018 paper in the Journal of Traditional and Complementary Medicine. Mice were given crape jasmine root extract orally (250, 500 or 1000 mg/kg) for 28 consecutive days, then received a single injection of amyloid-β(25-35) peptide directly into the brain’s ventricles — a standard way to model the amyloid plaque toxicity seen in Alzheimer’s disease. Memory was assessed using the novel object recognition test, a validated rodent behavioural measure. Mice that had received the plant extract showed less memory impairment, less neuronal loss in the hippocampus, and lower markers of lipid peroxidation (oxidative membrane damage) than mice that received the amyloid-β injection alone.

Here is the design detail that changes what this result can honestly claim. The extract was given before the amyloid-β insult, for 28 days, and the insult was a single acute injection rather than the slow, decades-long, multi-mechanism accumulation of pathology that defines actual human Alzheimer’s disease. This is a pretreatment, or prophylaxis, design — it tests whether pre-loading the brain with this extract blunts damage from an injury that has not happened yet, which is a different and easier question than the one a person with existing cognitive decline is actually asking, which is whether a treatment started after disease onset can help. The same evidence doctrine that governs every article on this site has flagged this exact pattern before in other herbs’ hepatoprotection and osteoporosis-prevention literature, and it applies here without modification: a positive prevention-model result in young, healthy, otherwise undamaged rodent brains does not establish that the same intervention would help a person who already has measurable disease.

Back to Table of Contents

A Traditional “Brain Tonic” Claim, Tested a Different Way

One further small study is worth including for completeness and because it illustrates a different traditional claim about this plant’s effect on the mind. A 2015 paper in the Avicenna Journal of Phytomedicine opens by naming crape jasmine’s traditional folklore uses as “anti-epileptic, anti-mania, brain tonic, and antioxidant,” then tests an ethanolic leaf extract in mice using the marble-burying test, a standard screen for obsessive-compulsive- and anxiety-like behaviour, with fluoxetine (an SSRI antidepressant) as the reference comparator. Despite the paper’s own title describing the extract as exacerbating burying behaviour, its results and conclusion sections state the opposite: the extract dose-dependently inhibited marble-burying behaviour, at a magnitude the authors describe as similar to fluoxetine, without affecting general motor activity. Read from the results and conclusion — the parts of a paper that carry its actual finding — this is a small, single-laboratory signal of anxiolytic- or anti-compulsive-like activity, not a stimulant one, sitting somewhat awkwardly next to the “rejuvenating tonic” framing under which this whole research area started. As with every comparator drug used in this literature, matching fluoxetine’s effect size in one mouse assay validates that the assay can detect an effect; it does not establish that this plant works like an SSRI, and it is not evidence of anything a person could safely replicate at home.

Back to Table of Contents

The Mechanism Ceiling: What Approved Drugs Already Show

This is the single most useful piece of context for reading every finding above, and it comes from outside crape jasmine’s own literature entirely. Acetylcholinesterase inhibition is not a novel or speculative mechanism — it is the mechanism of three drugs the U.S. Food and Drug Administration has approved for Alzheimer’s disease: donepezil, rivastigmine, and galantamine (the same drug this plant’s alkaloids are repeatedly benchmarked against in the studies above). Decades of clinical trials on those drugs have established, with a much larger and more rigorous evidence base than anything discussed on this page, that acetylcholinesterase inhibition produces a modest, symptomatic, non-disease-modifying benefit — it can improve cognitive test scores and daily function slightly for a period of time, it does not stop or reverse the underlying neurodegeneration, and its clinical effect size is small enough that some health systems debate its cost-effectiveness. Whatever crape jasmine’s own alkaloids ultimately turn out to contribute through this exact same mechanism, that established ceiling almost certainly applies. This is worth naming directly rather than leaving as an implication: no matter how good this plant’s laboratory numbers look, the mechanism they operate through has already been pushed about as far as it goes, by drugs specifically designed and dosed to exploit it, and the result was a modest effect.

The Same Mechanism, Both Ways

Raising acetylcholine is not a one-directional good. The main topic page already makes this point about organophosphate pesticides and nerve agents, which work by the same fundamental mechanism — acetylcholinesterase inhibition — taken to a lethal extreme. The pharmacology reviewed on this page adds detail to why that is not just a scary comparison but a real dosing continuum: at the low, controlled concentrations used in these laboratory assays, the effect is a measurable, reversible shift in synaptic signalling. At high, uncontrolled concentrations, the identical mechanism produces cholinergic crisis — excess salivation, sweating, vomiting, diarrhoea, a slowed heart rate, constricted pupils, muscle twitching, and, at the extreme, respiratory failure from excess secretions and diaphragm weakness. A manufactured acetylcholinesterase-inhibitor drug is titrated in small, defined steps specifically because this dose-response curve is narrow enough to matter clinically. An unstandardised plant preparation, by contrast, offers no such control: the same property that produces a therapeutic effect in a rat at a measured dose is the property that would produce toxicity in a person at an unmeasured one. This is not a reason to fear a garden shrub. It is the precise, mechanistic reason this plant is never given a dose anywhere on this site.

What Would Actually Settle This

Real Alzheimer’s and mild-cognitive-impairment trials use validated, standardised instruments specifically so that a result means something comparable across studies: the ADAS-Cog (Alzheimer’s Disease Assessment Scale—Cognitive Subscale), the CDR-SB (Clinical Dementia Rating—Sum of Boxes), and the MMSE (Mini-Mental State Examination) are the standard tools, alongside a defined minimum clinically important difference and, ideally, a biomarker or imaging endpoint. None of those tools has ever been applied to crape jasmine, in any preparation, in any human population. The electrophysiology and in-vivo rat work above is genuinely more mechanistically detailed than most plant “brain health” literature gets — but mechanistic detail in a rodent is not the same instrument, and naming the actual tools that exist and have simply never been pointed at this plant is more informative than a generic “more research is needed.”

Back to Table of Contents

Evidence Ledger for This Page

  1. Acetylcholinesterase inhibition, in-vitro enzyme assay, whole extract and isolated alkaloids. Tier: reproduced across at least four independent Thai research groups over roughly two decades. The deepest, most consistent finding on this plant.
  2. Two named bisindole alkaloids more potent than galanthamine in vitro. Tier: single bioassay-guided isolation study with a real negative control (two inactive related alkaloids).
  3. A quantified IC50 for a third named alkaloid. Tier: single study, real measured potency, real percentage yield from the source fraction.
  4. In-vivo rat cortical enzyme inhibition and neuronal activity marker. Tier: single real in-vivo pharmacodynamic study, biochemical/immunohistochemical endpoints, not behavioural.
  5. Ex-vivo hippocampal electrophysiology. Tier: single real study, direct synaptic-function readout, isolated tissue rather than a behaving animal.
  6. Prevention of amyloid-β-induced memory impairment in mice. Tier: single real behavioural study — but a pretreatment/prophylaxis design, testing prevention of an insult that has not happened, not treatment of existing pathology.
  7. Anxiolytic/anti-compulsive-like behavioural effect. Tier: single small study, real per the results and conclusion text despite a misleading title.
  8. Transdermal delivery formulation. Tier: single applied-pharmaceutics study, non-human skin model, no efficacy data.
  9. Human cognitive efficacy or safety data, in any preparation. Tier: absent, despite this being the plant’s single deepest preclinical evidence base.

Practical Guidance

Back to Table of Contents

Key Research Papers

  1. Ingkaninan K, De Best R, van der Heijden R, Hofte AJP, Karabatak B, Irth H, Tjaden UR, van der Greef J, Verpoorte R. Screening for acetylcholinesterase inhibitory activity in plants used in Thai traditional rejuvenating and neurotonic remedies. Journal of Ethnopharmacology, 2003. Find on PubMed.
  2. Ingkaninan K, Changwijit K, Suwanborirux K. Vobasinyl-iboga bisindole alkaloids, potent acetylcholinesterase inhibitors from Tabernaemontana divaricata root. Journal of Pharmacy and Pharmacology, 2006. Find on PubMed.
  3. Chattipakorn S, Pongpanparadorn A, Pratchayasakul W, Pongchaidacha A, Ingkaninan K, Chattipakorn N. Tabernaemontana divaricata extract inhibits neuronal acetylcholinesterase activity in rats. Journal of Ethnopharmacology, 2007. Find on PubMed.
  4. Pratchayasakul W, Pongchaidecha A, Chattipakorn N, Chattipakorn SC. Reversible acetylcholinesterase inhibitory effect of Tabernaemontana divaricata extract on synaptic transmission in rat CA1 hippocampus. Indian Journal of Medical Research, 2010. Find on PubMed.
  5. Chaiyana W, Schripsema J, Ingkaninan K, Okonogi S. 3′-R/S-hydroxyvoacamine, a potent acetylcholinesterase inhibitor from Tabernaemontana divaricata. Phytomedicine, 2013. Find on PubMed.
  6. Chaiyana W, Rades T, Okonogi S. Characterization and in vitro permeation study of microemulsions and liquid crystalline systems containing the anticholinesterase alkaloidal extract from Tabernaemontana divaricata. International Journal of Pharmaceutics, 2013. Find on PubMed.
  7. Khongsombat O, Nakdook W, Ingkaninan K. Inhibitory effects of Tabernaemontana divaricata root extract on oxidative stress and neuronal loss induced by amyloid β(25-35) peptide in mice. Journal of Traditional and Complementary Medicine, 2018. Pretreatment design — see above. Find on PubMed.
  8. Chanchal R, Balasubramaniam A, Navin R, Nadeem S. Tabernaemontana divaricata leaves extract exacerbate burying behavior in mice. Avicenna Journal of Phytomedicine, 2015. Read the results and conclusion, not only the title. Find on PubMed.
  9. Pratchayasakul W, Pongchaidecha A, Chattipakorn N, Chattipakorn S. Ethnobotany & ethnopharmacology of Tabernaemontana divaricata. Indian Journal of Medical Research, 2008. Review; documents 66 named alkaloids from this species and lists cholinergic enhancement among its reported properties. Find on PubMed.
  10. Naidoo CM, Naidoo Y, Dewir YH, Murthy HN, El-Hendawy S, Al-Suhaibani N. Major bioactive alkaloids and biological activities of Tabernaemontana species (Apocynaceae). Plants, 2021. Genus-wide confirmation of cholinergic/CNS activity as a recurring theme. Find on PubMed.

Back to Table of Contents

Connections

Back to Table of Contents